sirexatamab

Home
Ligands
sirexatamab

GtoPdb Ligand ID: 11760

Synonyms: DKN-01 | LY-2812176 | LY2812176

Comment: Sirexatamab (DKN-01, formerly LY-2812176) is a humanised, IgG4-κ anti-DKK1 (dickkopf WNT signaling pathway inhibitor 1) monoclonal antibody that was developed by Leap Therapeutics for potential anti-cancer activity [2,5].

References
1. Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA et al.. (2020) Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res, 26 (23): 6158-6167. [PMID:32878766]
2. Haas MS, Kagey MH, Heath H, Schuerpf F, Rottman JB, Newman W. (2021) mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment. Mol Cancer Res, 19 (4): 717-725. [PMID:33443105]
3. Katoh M, Katoh M. (2017) Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int J Mol Med, 40 (3): 587-606. [PMID:28731148]
4. Klempner SJ, Bendell JC, Villaflor VM, Tenner LL, Stein SM, Rottman JB, Naik GS, Sirard CA, Kagey MH, Chaney MF et al.. (2021) Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol Cancer Ther, 20 (11): 2240-2249. [PMID:34482288]
5. Wall JA, Klempner SJ, Arend RC. (2020) The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs, 29 (7): 639-644. [PMID:32408777]

References

1. Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA et al.. (2020)
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Clin Cancer Res, 26 (23): 6158-6167. [PMID:32878766]

2. Haas MS, Kagey MH, Heath H, Schuerpf F, Rottman JB, Newman W. (2021)
mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.
Mol Cancer Res, 19 (4): 717-725. [PMID:33443105]

3. Katoh M, Katoh M. (2017)
Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Int J Mol Med, 40 (3): 587-606. [PMID:28731148]

4. Klempner SJ, Bendell JC, Villaflor VM, Tenner LL, Stein SM, Rottman JB, Naik GS, Sirard CA, Kagey MH, Chaney MF et al.. (2021)
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Mol Cancer Ther, 20 (11): 2240-2249. [PMID:34482288]

5. Wall JA, Klempner SJ, Arend RC. (2020)
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Expert Opin Investig Drugs, 29 (7): 639-644. [PMID:32408777]